Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan

Journal of Nephrology

Volumn 15, Issue 4, 2002, Pages 368-373

  Hsieh, Ming Chia ^a   Lin, Shiu Ru ^a   Yang, Yuan Chieh ^a   Chen, Hung Chun ^a   Lin, Jiun Nong ^a   Shin, Shyi Jang ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apo E genotype; Diabetic nephropathy; Taiwan; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ISOPROTEIN; LIPID; LIPOPROTEIN; PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIAGNOSTIC PROCEDURE; DIALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; KIDNEY FAILURE; LIPIDOSIS; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; STATISTICAL SIGNIFICANCE; TAIWAN;

ADULT; AGE DISTRIBUTION; AGED; ALLELES; ANALYSIS OF VARIANCE; APOLIPOPROTEINS A; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SEX DISTRIBUTION; TAIWAN;

EID: 0036659004     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Lai YH, Hwang SJ, Yang WC, and the dialysis surveillance committee. 1997 National Dialysis Surveillance in Taiwan. ROC 1997; 11: 177-214.
2. Li LS. End-stage renal disease in China. Kidney Int 1996; 49: 287-301.
3. Tarnow L. Genetic pattern in diabetic nephropathy. Nephrol Dial Transplant 1996; 11: 410-2.
4. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1990; 33: 438-43.
5. Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in African-Americans with non-insulin dependent diabetes mellitus. Am J Kidney Dis 1995; 25: 710-3.
6. Diamond JR, Karnowsky MJ. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 1987; 32: 671-7.
7. Kasiske BL, O'Donnell M, Cleary MP, Keane WF. Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int 1989; 35: 40-8.
8. Mulec H, Johnson S-AA, Bjorck S. Relation between serum cholesterol and diabetic nephropathy. Lancet 1990; 335: 1537-8.
9. Sasaki T, Kurata H, Omura K, Utsunomiya K, Ikeda Y. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med 1990; 29: 156-63.
10. Shoji T, Nishizawa Y, Toyokawa A, Kawagishi T, Okuno Y, Morii H. Decreased albuminuria by pravastatin in hyperlipidemic diabetics. Nephron 1991; 59: 664-5.
11. Lam KS, Cheng JK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-9.
12. Siest G, Pillot T, Regis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, Visvikis S. Apolipoprotein E: An important gene and protein to follow in laboratory medicine. Clin Chem 1995; 41: 1068-86.
13. Eto M, Watanabe K, Ishii K. A racial difference in apolipoprotein E allele frequencies between the Japanese and Caucasian populations. Clin Genet 1986; 30: 422-7.
14. Asakawa J, Takahashi N, Rosenblum BB, Neel JV. Two-dimensional gel studies of genetic variation in the plasma proteins of American-Indians and Japanese. Hum Genet 1985; 70: 222-230.
15. Tsuchiya S, Yamamouchi Y, Onuki M, Yamakawa K, Miyazaki R, Taya T, Kondo I. Frequencies of apolipoproteins E5 and E7 in apparently healthy Japanese. Jpn J Hum Genet 1985; 30: 271-8.
16. Onuma T, Laffel LM, Angelico MC, Krolewski AS. Apolipoprotein E genotype and risk of diabetic nephropathy. J Am Soc Nephrol 1996; 7: 1075-8.
17. Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 1998; 31: 666-73.
18. Horita K, Eto M, Makino I. Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 1994; 107: 203-11.
19. Boize R, Benhamou PY, Corticelli P, Valenti K, Bosson JL, Halimi S. Apo E polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM. Nephrol Dial Transplant 1998; 13: 72-5.
20. Kataoka S, Robbins DC, Cowan LD, Go O, Yeh JL, Devereux RB, Fabsitz RR. Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes: the strong heart study. Arterioscler Thromb Vasc Biol 1996; 16: 918-925.
21. Evans AE, Zhang W, Moreel JF, Bard JM, Ricard S, Poirier O, Tiret L. Polymorphisms of the apolipoprotein B and E genes and their relationship to plasma lipid variables in healthy Chinese men. Hum Genet 1993; 92: 191-7.
22. Wang KQ, He JL, Xie YH. Studies on human apolipoprotein E genetic isoforms and their phenotypes among the Chinese population. Proc Chin Acad Med Sci Peking Union Med Coll 1987; 2: 133-9.
23. Yen YC, Liu CK, Lung FW, Chong MY. Apolipoprotein E polymorphism and Alzheimer's disease. Kaohsiung J Med Sci 2001; 71: 190-7.
24. Ha SK, Park HS, Kim KW, Kim SJ, Kim DH, Kim JH, Lee HY. Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 1999; 14: 2144-9.
25. Lane PH, Stefes MW, Mauner M. Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes 1992; 41: 581-6.
26. Ritz E, Keller CK, Bergis HK, Siebels M. Renal involvement in type II diabetes. Curr Opin Nephrol Hypertens 1994; 3: 137-44.
27. Paving HH, Gall MA, Skott P. Prevalence and cause of albuminuria in non-insulin dependent diabetic patients. Kidney Int 1987; 41: 758-62.
28. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31: 673-89.
29. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-30.
30. Kim JH, Lee EJ, Kwon OH. Apolipoprotein E genotyping and phenotyping in type II diabetes mellitus patients with hypertriglyceridemia. Clin Biochem 1997; 30: 47-52.
31. Soedamah-Muthu SS, Colhoun HM, Taskinen MR, Idzior-Walus B, Fuller JH. Differences in HDL-cholesterol:apoA-1 + apoA-II ratio and apoE phenotype with albuminuric status in Type 1 diabetic patients. Diabetologia 2000; 43: 1353-9.
32. Inamdar PA, Kelkar SM, Devasagayam TPA, Bapat MM. Apolipoprotein E polymorphism in non-insulin-dependent diabetics of Mumbai, India and its effect on plasma lipids and lipoproteins. Diabetes Res Clin Prat 2000; 47: 217-23.
33. Kaysen G. Hyperlipidemia of the nephrotic syndrome. Kidney Int 1990; 39 (suppl 31): S8-15.
34. Warwick GL, Caslake MJ, Boulton-Jones JM, Dagen M, Packard CJ, Shepherd J. Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 1990; 39: 187-92.
35. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int 1999; 56 (suppl 71): S22-4.
36. Attman PO, Knight-Gibson C, Tavella M, Smuelsson O, Alaupovic P. The compositional abnormalities of lipoproteins in diabetic renal failure. Nephrol Dial Transplant 1998; 13: 2833-41.
37. Groop PH, Elliott T, Ekstrand A. Multiple lipoprotein abnormalities in type I diabetic patients with renal disease. Diabetes 1996; 45: 974-9.
38. Jerums G, Allen TJ, Tsalamandris C. Relationship of progressively increasing albuminuria to apoprotein (a) and blood pressure in type 2 (non insulin-dependent) and type 1 (insulin-dependent) diabetic patients. Diabetologia 1993; 123: 57-72.
39. Kao JT, Tsai KS, Chang CJ, Huang PC. The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population. Atherosclerosis 1995; 114: 55-9.
40. Blue ML, Williams DL, Zucker S, Khan SA, Blum CB. Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proc Natl Acad Sci USA 1983; 80: 283-7.
41. Camejo G, Hurt-Camejo E, Olsson U, Bondjers G. Proteoglycans and lipoproteins in atherosclerosis. Curr Opin Lipidol 1993; 4: 385-91.
42. Saito T, Sato H, Oikawa S, Kudo K, Kurihara I, Nakayama K, Abe K, Yoshinaga K, Sakaguchi H. Lipoprotein glomerulopathy: report of a normolipidemic case and review of the literature. Am J Nephrol 1993; 13: 64-8.
43. Araki SI, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS. APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes. Diabetes 2000; 49: 21090-5.